Preservation From Left Ventricular Remodeling by Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Use of Granulocyte-Colony–Stimulating Factor (FIRSTLINE-AMI)

Background— Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony–stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNC CD34+ ), we tested the impact of G-CSF integrated into primary percutaneous coronary interv...

Full description

Saved in:
Bibliographic Details
Published inCirculation (New York, N.Y.) Vol. 112; no. 20; pp. 3097 - 3106
Main Authors Ince, Hüseyin, Petzsch, Michael, Kleine, Hans Dieter, Schmidt, Heike, Rehders, Tim, Körber, Thomas, Schümichen, Carl, Freund, Mathias, Nienaber, Christoph A.
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 15.11.2005
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background— Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony–stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNC CD34+ ), we tested the impact of G-CSF integrated into primary percutaneous coronary intervention (PCI) management of acute myocardial infarction in man. Methods and Results— Fifty consecutive patients with ST-segment elevation myocardial infarction were subjected to primary PCI stenting with abciximab and followed up for 6 months; 89±35 minutes after successful PCI, 25 patients were randomly assigned in this pilot study (PROBE design) to receive subcutaneous G-CSF at 10 μg/kg body weight for 6 days in addition to standard care, including aspirin, clopidogrel, an ACE inhibitor, β-blocking agents, and statins. By use of CellQuest software on peripheral blood samples incubated with CD45 and CD34, mobilized MNC CD34+ were quantified on a daily basis. With homogeneous demographics and clinical and infarct-related characteristics, G-CSF stimulation led to mobilization of MNC CD34+ to between 3.17±2.93 MNC CD34+ /μL at baseline and 64.55±37.11 MNC CD34+ /μL on day 6 ( P <0.001 versus control); there was no indication of leukocytoclastic effects, significant pain, impaired rheology, inflammatory reactions, or accelerated restenosis at 6 months. Within 35 days, G-CSF and MNC CD34+ liberation led to enhanced resting wall thickening in the infarct zone of between 0.29±0.22 and 0.99±0.32 mm versus 0.49±0.29 mm in control subjects ( P <0.001); under inotropic challenge with dobutamine (10 μg · kg −1 · min −1 ), wall motion score index showed improvement from 1.66±0.23 to 1.41±0.21 ( P <0.004 versus control) and to 1.35±0.24 after 4 months ( P <0.001 versus control), respectively, coupled with sustained recovery of wall thickening to 1.24±0.31 mm ( P <0.001 versus control) at 4 months. Accordingly, resting wall motion score index improved with G-CSF to 1.41±0.25 ( P <0.001 versus control), left ventricular end-diastolic diameter to 55±5 mm ( P <0.002 versus control), and ejection fraction to 54±8% ( P <0.001 versus control) after 4 months. Morphological and functional improvement with G-CSF was corroborated by enhanced metabolic activity and 18 F-deoxyglucose uptake in the infarct zone ( P <0.001 versus control). Conclusions— G-CSF and mobilization of MNC CD34+ after reperfusion of infarcted myocardium may offer a pragmatic strategy for preservation of myocardium and prevention of remodeling without evidence of aggravated restenosis.
AbstractList Background— Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony–stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNC CD34+ ), we tested the impact of G-CSF integrated into primary percutaneous coronary intervention (PCI) management of acute myocardial infarction in man. Methods and Results— Fifty consecutive patients with ST-segment elevation myocardial infarction were subjected to primary PCI stenting with abciximab and followed up for 6 months; 89±35 minutes after successful PCI, 25 patients were randomly assigned in this pilot study (PROBE design) to receive subcutaneous G-CSF at 10 μg/kg body weight for 6 days in addition to standard care, including aspirin, clopidogrel, an ACE inhibitor, β-blocking agents, and statins. By use of CellQuest software on peripheral blood samples incubated with CD45 and CD34, mobilized MNC CD34+ were quantified on a daily basis. With homogeneous demographics and clinical and infarct-related characteristics, G-CSF stimulation led to mobilization of MNC CD34+ to between 3.17±2.93 MNC CD34+ /μL at baseline and 64.55±37.11 MNC CD34+ /μL on day 6 ( P <0.001 versus control); there was no indication of leukocytoclastic effects, significant pain, impaired rheology, inflammatory reactions, or accelerated restenosis at 6 months. Within 35 days, G-CSF and MNC CD34+ liberation led to enhanced resting wall thickening in the infarct zone of between 0.29±0.22 and 0.99±0.32 mm versus 0.49±0.29 mm in control subjects ( P <0.001); under inotropic challenge with dobutamine (10 μg · kg −1 · min −1 ), wall motion score index showed improvement from 1.66±0.23 to 1.41±0.21 ( P <0.004 versus control) and to 1.35±0.24 after 4 months ( P <0.001 versus control), respectively, coupled with sustained recovery of wall thickening to 1.24±0.31 mm ( P <0.001 versus control) at 4 months. Accordingly, resting wall motion score index improved with G-CSF to 1.41±0.25 ( P <0.001 versus control), left ventricular end-diastolic diameter to 55±5 mm ( P <0.002 versus control), and ejection fraction to 54±8% ( P <0.001 versus control) after 4 months. Morphological and functional improvement with G-CSF was corroborated by enhanced metabolic activity and 18 F-deoxyglucose uptake in the infarct zone ( P <0.001 versus control). Conclusions— G-CSF and mobilization of MNC CD34+ after reperfusion of infarcted myocardium may offer a pragmatic strategy for preservation of myocardium and prevention of remodeling without evidence of aggravated restenosis.
Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony-stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNCCD34+), we tested the impact of G-CSF integrated into primary percutaneous coronary intervention (PCI) management of acute myocardial infarction in man.BACKGROUNDConsidering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony-stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNCCD34+), we tested the impact of G-CSF integrated into primary percutaneous coronary intervention (PCI) management of acute myocardial infarction in man.Fifty consecutive patients with ST-segment elevation myocardial infarction were subjected to primary PCI stenting with abciximab and followed up for 6 months; 89+/-35 minutes after successful PCI, 25 patients were randomly assigned in this pilot study (PROBE design) to receive subcutaneous G-CSF at 10 microg/kg body weight for 6 days in addition to standard care, including aspirin, clopidogrel, an ACE inhibitor, beta-blocking agents, and statins. By use of CellQuest software on peripheral blood samples incubated with CD45 and CD34, mobilized MNCCD34+ were quantified on a daily basis. With homogeneous demographics and clinical and infarct-related characteristics, G-CSF stimulation led to mobilization of MNCCD34+ to between 3.17+/-2.93 MNCCD34+/microL at baseline and 64.55+/-37.11 MNCCD34+/microL on day 6 (P<0.001 versus control); there was no indication of leukocytoclastic effects, significant pain, impaired rheology, inflammatory reactions, or accelerated restenosis at 6 months. Within 35 days, G-CSF and MNCCD34+ liberation led to enhanced resting wall thickening in the infarct zone of between 0.29+/-0.22 and 0.99+/-0.32 mm versus 0.49+/-0.29 mm in control subjects (P<0.001); under inotropic challenge with dobutamine (10 microg.kg(-1).min(-1)), wall motion score index showed improvement from 1.66+/-0.23 to 1.41+/-0.21 (P<0.004 versus control) and to 1.35+/-0.24 after 4 months (P<0.001 versus control), respectively, coupled with sustained recovery of wall thickening to 1.24+/-0.31 mm (P<0.001 versus control) at 4 months. Accordingly, resting wall motion score index improved with G-CSF to 1.41+/-0.25 (P<0.001 versus control), left ventricular end-diastolic diameter to 55+/-5 mm (P<0.002 versus control), and ejection fraction to 54+/-8% (P<0.001 versus control) after 4 months. Morphological and functional improvement with G-CSF was corroborated by enhanced metabolic activity and 18F-deoxyglucose uptake in the infarct zone (P<0.001 versus control).METHODS AND RESULTSFifty consecutive patients with ST-segment elevation myocardial infarction were subjected to primary PCI stenting with abciximab and followed up for 6 months; 89+/-35 minutes after successful PCI, 25 patients were randomly assigned in this pilot study (PROBE design) to receive subcutaneous G-CSF at 10 microg/kg body weight for 6 days in addition to standard care, including aspirin, clopidogrel, an ACE inhibitor, beta-blocking agents, and statins. By use of CellQuest software on peripheral blood samples incubated with CD45 and CD34, mobilized MNCCD34+ were quantified on a daily basis. With homogeneous demographics and clinical and infarct-related characteristics, G-CSF stimulation led to mobilization of MNCCD34+ to between 3.17+/-2.93 MNCCD34+/microL at baseline and 64.55+/-37.11 MNCCD34+/microL on day 6 (P<0.001 versus control); there was no indication of leukocytoclastic effects, significant pain, impaired rheology, inflammatory reactions, or accelerated restenosis at 6 months. Within 35 days, G-CSF and MNCCD34+ liberation led to enhanced resting wall thickening in the infarct zone of between 0.29+/-0.22 and 0.99+/-0.32 mm versus 0.49+/-0.29 mm in control subjects (P<0.001); under inotropic challenge with dobutamine (10 microg.kg(-1).min(-1)), wall motion score index showed improvement from 1.66+/-0.23 to 1.41+/-0.21 (P<0.004 versus control) and to 1.35+/-0.24 after 4 months (P<0.001 versus control), respectively, coupled with sustained recovery of wall thickening to 1.24+/-0.31 mm (P<0.001 versus control) at 4 months. Accordingly, resting wall motion score index improved with G-CSF to 1.41+/-0.25 (P<0.001 versus control), left ventricular end-diastolic diameter to 55+/-5 mm (P<0.002 versus control), and ejection fraction to 54+/-8% (P<0.001 versus control) after 4 months. Morphological and functional improvement with G-CSF was corroborated by enhanced metabolic activity and 18F-deoxyglucose uptake in the infarct zone (P<0.001 versus control).G-CSF and mobilization of MNC(CD34+) after reperfusion of infarcted myocardium may offer a pragmatic strategy for preservation of myocardium and prevention of remodeling without evidence of aggravated restenosis.CONCLUSIONSG-CSF and mobilization of MNC(CD34+) after reperfusion of infarcted myocardium may offer a pragmatic strategy for preservation of myocardium and prevention of remodeling without evidence of aggravated restenosis.
Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony-stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNCCD34+), we tested the impact of G-CSF integrated into primary percutaneous coronary intervention (PCI) management of acute myocardial infarction in man. Fifty consecutive patients with ST-segment elevation myocardial infarction were subjected to primary PCI stenting with abciximab and followed up for 6 months; 89+/-35 minutes after successful PCI, 25 patients were randomly assigned in this pilot study (PROBE design) to receive subcutaneous G-CSF at 10 microg/kg body weight for 6 days in addition to standard care, including aspirin, clopidogrel, an ACE inhibitor, beta-blocking agents, and statins. By use of CellQuest software on peripheral blood samples incubated with CD45 and CD34, mobilized MNCCD34+ were quantified on a daily basis. With homogeneous demographics and clinical and infarct-related characteristics, G-CSF stimulation led to mobilization of MNCCD34+ to between 3.17+/-2.93 MNCCD34+/microL at baseline and 64.55+/-37.11 MNCCD34+/microL on day 6 (P<0.001 versus control); there was no indication of leukocytoclastic effects, significant pain, impaired rheology, inflammatory reactions, or accelerated restenosis at 6 months. Within 35 days, G-CSF and MNCCD34+ liberation led to enhanced resting wall thickening in the infarct zone of between 0.29+/-0.22 and 0.99+/-0.32 mm versus 0.49+/-0.29 mm in control subjects (P<0.001); under inotropic challenge with dobutamine (10 microg.kg(-1).min(-1)), wall motion score index showed improvement from 1.66+/-0.23 to 1.41+/-0.21 (P<0.004 versus control) and to 1.35+/-0.24 after 4 months (P<0.001 versus control), respectively, coupled with sustained recovery of wall thickening to 1.24+/-0.31 mm (P<0.001 versus control) at 4 months. Accordingly, resting wall motion score index improved with G-CSF to 1.41+/-0.25 (P<0.001 versus control), left ventricular end-diastolic diameter to 55+/-5 mm (P<0.002 versus control), and ejection fraction to 54+/-8% (P<0.001 versus control) after 4 months. Morphological and functional improvement with G-CSF was corroborated by enhanced metabolic activity and 18F-deoxyglucose uptake in the infarct zone (P<0.001 versus control). G-CSF and mobilization of MNC(CD34+) after reperfusion of infarcted myocardium may offer a pragmatic strategy for preservation of myocardium and prevention of remodeling without evidence of aggravated restenosis.
Author Körber, Thomas
Freund, Mathias
Petzsch, Michael
Ince, Hüseyin
Rehders, Tim
Schümichen, Carl
Schmidt, Heike
Nienaber, Christoph A.
Kleine, Hans Dieter
Author_xml – sequence: 1
  givenname: Hüseyin
  surname: Ince
  fullname: Ince, Hüseyin
  organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany
– sequence: 2
  givenname: Michael
  surname: Petzsch
  fullname: Petzsch, Michael
  organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany
– sequence: 3
  givenname: Hans Dieter
  surname: Kleine
  fullname: Kleine, Hans Dieter
  organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany
– sequence: 4
  givenname: Heike
  surname: Schmidt
  fullname: Schmidt, Heike
  organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany
– sequence: 5
  givenname: Tim
  surname: Rehders
  fullname: Rehders, Tim
  organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany
– sequence: 6
  givenname: Thomas
  surname: Körber
  fullname: Körber, Thomas
  organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany
– sequence: 7
  givenname: Carl
  surname: Schümichen
  fullname: Schümichen, Carl
  organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany
– sequence: 8
  givenname: Mathias
  surname: Freund
  fullname: Freund, Mathias
  organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany
– sequence: 9
  givenname: Christoph A.
  surname: Nienaber
  fullname: Nienaber, Christoph A.
  organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17283722$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16275869$$D View this record in MEDLINE/PubMed
BookMark eNqNks1u1DAQxyNURLeFV0DmAIJDltiJ83FCUbTbRkpbtB9cI68zqYwcu7WdlZYT78C78QA8Cd4PVMGJ02hmfvMfzcdFcKa0giB4g6Mpxin-WNWLat2Uq_rutrwupziiU5rgJI6fBRNMSRImNC7OgkkURUWYxYScBxfWfvVuGmf0RXCOU5LRPC0mwc_PBiyYLXNCKzQ3ekAN9A59AeWM4KNkBi1g0B1Ioe7RZrdnlAtr5eDeMAedT2-ZPZDi21GGqQ4tHQyoAilRIzZgjgmh0Gyr5XYvVfLRAbrZac5MJ5hEteqZ4QfOt1lbQLpHV4apUWq-cxBWWmq1-_X9x9KJwfdze5k5404b9H5eL5arpr6dheVN_eFl8Lxn0sKrk70M1vPZqroOm7uruiqbkNOIupDhnPtV9byHjBQFJBEUOE1ZweKebApKKYv61Hs4J3nGEsgKBmlSJMCh8za-DN4ddR-MfhzBunYQlvupmQI92jbN84hEhHjw9QkcNwN07YMRAzO79s8lPPD2BPhlMtn7ubmwT1xG8jg7CBVHjhttrYH-CYna_Xe0f3-HD9P2-B2-9tM_tVy4w2WcYUL-h8Jv3ynHEA
CODEN CIRCAZ
CitedBy_id crossref_primary_10_1016_j_jacc_2005_12_051
crossref_primary_10_1016_j_jacc_2010_05_039
crossref_primary_10_1517_14712598_8_11_1675
crossref_primary_10_1016_j_pcad_2007_03_004
crossref_primary_10_1016_j_ahj_2006_03_012
crossref_primary_10_4061_2010_579142
crossref_primary_10_17996_anc_19_00099
crossref_primary_10_3109_14653240903580262
crossref_primary_10_1146_annurev_physiol_012110_142230
crossref_primary_10_1007_s10741_007_9047_9
crossref_primary_10_18705_1607_419X_2007_13_3_208_211
crossref_primary_10_2217_17460751_3_2_189
crossref_primary_10_5551_jat_2279
crossref_primary_10_1002_jso_23014
crossref_primary_10_1016_j_ijcard_2009_02_020
crossref_primary_10_1136_heartjnl_2013_304955
crossref_primary_10_1021_acsnano_3c02781
crossref_primary_10_1016_j_thromres_2010_11_004
crossref_primary_10_1002_prp2_451
crossref_primary_10_1016_j_jacc_2006_06_058
crossref_primary_10_1016_j_ahj_2008_03_024
crossref_primary_10_1183_09031936_00034810
crossref_primary_10_1016_j_atherosclerosis_2007_03_046
crossref_primary_10_1093_cvr_cvn202
crossref_primary_10_1016_j_amjcard_2007_03_036
crossref_primary_10_1007_s10557_007_6072_9
crossref_primary_10_1016_j_bbrc_2011_05_081
crossref_primary_10_1111_j_1549_8719_2010_00051_x
crossref_primary_10_1016_j_ijcard_2008_08_033
crossref_primary_10_1007_s12265_010_9207_5
crossref_primary_10_1007_s00586_011_2020_2
crossref_primary_10_1111_j_1365_2362_2007_01861_x
crossref_primary_10_1253_circj_CJ_11_0142
crossref_primary_10_1586_14779072_6_5_703
crossref_primary_10_2217_fca_10_109
crossref_primary_10_1016_j_scr_2011_05_003
crossref_primary_10_1097_HCO_0b013e3280210657
crossref_primary_10_1111_j_1600_0643_2007_00663_x
crossref_primary_10_1016_S0120_5633_11_70173_5
crossref_primary_10_1016_j_bbrc_2006_03_081
crossref_primary_10_4252_wjsc_v2_i4_61
crossref_primary_10_1016_j_ijcard_2006_11_074
crossref_primary_10_1016_S1131_3587_13_70096_7
crossref_primary_10_1586_erm_09_80
crossref_primary_10_1007_BF03345729
crossref_primary_10_1038_oby_2009_494
crossref_primary_10_1016_j_yjmcc_2008_08_003
crossref_primary_10_1007_s11897_009_0034_4
crossref_primary_10_1016_j_jacc_2006_09_018
crossref_primary_10_1016_j_jacc_2006_07_044
crossref_primary_10_1093_eurheartj_ehx248
crossref_primary_10_1038_mt_2009_40
crossref_primary_10_1111_j_1365_2362_2007_01876_x
crossref_primary_10_1157_13101639
crossref_primary_10_1007_s11897_007_0013_6
crossref_primary_10_2337_db15_0433
crossref_primary_10_1016_j_ijcard_2007_05_007
crossref_primary_10_1177_1074248407303139
crossref_primary_10_1152_ajpheart_00774_2008
crossref_primary_10_1016_j_jacc_2007_11_073
crossref_primary_10_1016_j_stem_2008_10_017
crossref_primary_10_1007_s00586_012_2213_3
crossref_primary_10_1002_ccd_25566
crossref_primary_10_1016_j_ijcard_2008_11_120
crossref_primary_10_1093_eurheartj_sul060
crossref_primary_10_1016_j_ijcard_2018_01_144
crossref_primary_10_1111_j_1540_8159_2007_00630_x
crossref_primary_10_1016_j_ahj_2006_11_004
crossref_primary_10_1016_S0145_4145_08_70143_6
crossref_primary_10_1016_j_ijcard_2012_10_089
crossref_primary_10_1016_j_yjmcc_2011_12_016
crossref_primary_10_1080_07853890701513746
crossref_primary_10_1093_cvr_cvs132
crossref_primary_10_1111_1755_5922_12032
crossref_primary_10_1038_ncpcardio0748
crossref_primary_10_1038_ncpcardio0745
crossref_primary_10_1002_14651858_CD008844_pub2
crossref_primary_10_1016_S0025_7753_08_75491_5
crossref_primary_10_1016_j_jacc_2006_02_021
crossref_primary_10_1016_j_yjmcc_2006_11_015
crossref_primary_10_1007_s00108_006_1707_7
crossref_primary_10_1016_j_yjmcc_2008_02_277
crossref_primary_10_1007_s11033_011_0703_8
crossref_primary_10_1097_CRD_0b013e31817bd7ab
crossref_primary_10_1016_j_bbrc_2009_10_074
crossref_primary_10_1007_s00395_011_0183_y
crossref_primary_10_1016_j_pcad_2007_03_001
crossref_primary_10_1007_s10741_006_9486_8
crossref_primary_10_1007_s00063_009_1054_2
crossref_primary_10_1007_s12020_013_9936_8
crossref_primary_10_1016_j_tips_2007_09_002
crossref_primary_10_1080_14017430701601651
crossref_primary_10_1002_jgm_1434
crossref_primary_10_1007_s10557_006_8285_8
crossref_primary_10_1186_1479_5876_7_106
crossref_primary_10_1038_ncpcardio0737
crossref_primary_10_1016_j_jtcvs_2014_06_029
crossref_primary_10_1253_jjcsc_16_1_83
crossref_primary_10_2459_JCM_0b013e328329ac77
crossref_primary_10_1016_j_yexcr_2019_01_001
crossref_primary_10_1038_ncpcardio0731
crossref_primary_10_1111_j_1365_2613_2009_00646_x
crossref_primary_10_1517_14712598_6_5_427
crossref_primary_10_1016_j_cyto_2017_10_012
crossref_primary_10_1152_ajpheart_00186_2009
crossref_primary_10_1002_dvdy_21258
crossref_primary_10_3892_mmr_2019_10120
crossref_primary_10_1016_j_lfs_2010_01_004
crossref_primary_10_1097_MOT_0b013e32830fdfc4
crossref_primary_10_1016_j_transci_2008_04_003
crossref_primary_10_1016_j_hlc_2008_09_006
crossref_primary_10_1146_annurev_pathol_2_010506_092038
crossref_primary_10_1080_14653240701431176
crossref_primary_10_1007_s12265_008_9055_8
crossref_primary_10_1080_08977190802090614
crossref_primary_10_1093_eurjhf_hfr148
crossref_primary_10_1586_14779072_4_5_745
crossref_primary_10_1016_j_athoracsur_2011_01_021
crossref_primary_10_1016_j_poamed_2015_09_001
crossref_primary_10_3109_00365513_2012_750010
crossref_primary_10_1016_j_ijcard_2007_06_067
crossref_primary_10_1016_j_ijcard_2009_03_030
crossref_primary_10_1016_j_ahj_2007_06_038
crossref_primary_10_33678_cor_2006_057
crossref_primary_10_1016_j_yjmcc_2006_10_001
crossref_primary_10_4155_tde_12_50
crossref_primary_10_1016_j_resp_2009_10_003
crossref_primary_10_1016_j_cytogfr_2018_08_003
crossref_primary_10_5124_jkma_2006_49_11_1035
crossref_primary_10_1007_s10741_010_9188_0
crossref_primary_10_1016_j_ahj_2006_09_003
crossref_primary_10_1152_ajpheart_00060_2012
crossref_primary_10_1007_s12265_008_9020_6
crossref_primary_10_1007_s10741_010_9165_7
crossref_primary_10_1016_j_ijcard_2011_11_030
crossref_primary_10_1016_j_ijcard_2008_04_004
crossref_primary_10_1007_s11936_006_0037_3
crossref_primary_10_1182_blood_2006_07_036202
crossref_primary_10_1371_journal_pone_0202823
crossref_primary_10_1016_j_exphem_2008_01_005
crossref_primary_10_1152_ajpheart_00130_2012
crossref_primary_10_1093_eurheartj_sun049
crossref_primary_10_1016_j_yjmcc_2015_07_021
crossref_primary_10_1097_BRS_0000000000000121
crossref_primary_10_1155_2012_817364
crossref_primary_10_1016_j_ijcard_2007_07_139
crossref_primary_10_1111_j_1582_4934_2009_00759_x
crossref_primary_10_1016_j_yjmcc_2011_05_015
crossref_primary_10_1016_j_ijcard_2010_04_018
crossref_primary_10_1016_j_biocel_2006_04_010
crossref_primary_10_1016_j_pharmthera_2010_09_011
crossref_primary_10_1111_j_1527_5299_2007_07111_x
crossref_primary_10_2459_JCM_0b013e328343d708
crossref_primary_10_1093_eurheartj_sun047
crossref_primary_10_1093_eurheartj_sun046
crossref_primary_10_1016_j_jacc_2015_03_563
crossref_primary_10_1111_j_1748_1716_2011_02259_x
crossref_primary_10_1016_j_stem_2009_02_013
crossref_primary_10_1517_14712590903460286
crossref_primary_10_1016_j_crvi_2007_05_004
crossref_primary_10_1177_0748233712440136
crossref_primary_10_1016_j_exphem_2008_01_012
crossref_primary_10_1007_s10238_021_00682_3
crossref_primary_10_1016_j_trim_2006_08_005
crossref_primary_10_1016_S1885_5857_07_60168_6
crossref_primary_10_1007_s00108_006_1610_2
crossref_primary_10_1016_j_ijcard_2008_10_029
crossref_primary_10_1253_circj_CJ_08_1129
crossref_primary_10_1182_blood_2006_06_030577
crossref_primary_10_1016_j_yasu_2011_03_001
crossref_primary_10_1182_blood_2010_05_286963
crossref_primary_10_1007_s10557_006_8799_0
crossref_primary_10_1016_j_exphem_2008_01_010
crossref_primary_10_1016_j_ijcard_2011_12_007
crossref_primary_10_1007_s00395_006_0605_4
crossref_primary_10_1016_j_ijcard_2006_11_016
crossref_primary_10_1016_j_trsl_2009_06_009
crossref_primary_10_1089_wound_2012_0390
crossref_primary_10_1016_j_exphem_2008_01_008
crossref_primary_10_1016_j_jacc_2015_03_571
crossref_primary_10_1016_j_ijcard_2009_04_047
crossref_primary_10_1096_fj_05_4763fje
crossref_primary_10_1586_erd_10_78
crossref_primary_10_1253_circj_CJ_10_0109
crossref_primary_10_1093_cvr_cvq301
crossref_primary_10_1093_ageing_afp244
crossref_primary_10_1093_eurheartj_sun051
Cites_doi 10.1016/S0735-1097(98)00395-7
10.1016/0735-1097(96)00152-0
10.1038/nm1199
10.1038/86498
10.1016/0735-1097(94)90667-X
10.1161/01.cir.0000147609.39780.02
10.7326/0003-4819-134-8-200104170-00011
10.1046/j.1365-2141.1997.8532481.x
10.1096/fj.03-0637fje
10.1161/01.cir.0000034046.87607.1c
10.1161/01.cir.0000129770.93985.3e
10.1161/circ.100.suppl_2.Ii-247
10.1038/35070587
10.1161/01.res.0000151843.79801.60
10.1161/circ.103.23.2776
10.1056/NEJMoa012081
10.1016/S0140-6736(04)15689-4
10.1161/01.cir.0000027585.05868.67
10.1161/circ.98.24.2695
10.1161/circ.105.4.539
10.1097/00062752-200105000-00005
10.1016/S0195-668X(02)00618-8
10.1016/S0092-8674(01)00409-3
10.1161/01.cir.0000025609.13806.31
10.1016/S0140-6736(03)14232-8
10.1016/j.yjmcc.2004.03.005
10.1038/nature02446
10.1073/pnas.181177898
10.1172/JCI119070
10.1067/mtc.2002.120716
10.1038/nature02460
10.1002/stem.140090
10.1016/S0894-7317(89)80014-8
10.1097/00003072-199601000-00005
10.1023/A:1005768523234
10.1038/nm0898-929
10.1016/S0092-8674(01)00328-2
10.1161/circ.102.19.2329
10.1056/NEJM200009283431303
10.7326/0003-4819-134-8-200104170-00012
10.1161/01.cir.0000062649.63838.c9
10.1038/nm912
10.1161/01.cir.0000051460.85800.bb
10.1111/j.1749-6632.2001.tb03591.x
10.1016/S0140-6736(03)12110-1
10.1161/01.cir.0000099501.52718.70
10.1056/NEJM200106213442503
10.1016/S0140-6736(04)15695-X
10.1007/BF01728306
10.1161/01.cir.0000084828.50310.6a
10.1161/circ.81.4.2138525
10.1016/0002-9149(66)90191-3
10.1016/j.jacc.2004.08.014
ContentType Journal Article
Copyright 2006 INIST-CNRS
Copyright_xml – notice: 2006 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1161/CIRCULATIONAHA.105.541433
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1524-4539
EndPage 3106
ExternalDocumentID 16275869
17283722
10_1161_CIRCULATIONAHA_105_541433
Genre Randomized Controlled Trial
Journal Article
GroupedDBID ---
.-D
.3C
.55
.GJ
.XZ
.Z2
01R
0R~
0ZK
18M
1J1
29B
2FS
2WC
354
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
6PF
71W
77Y
7O~
AAAAV
AAAXR
AAEJM
AAFWJ
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AARTV
AASOK
AAUEB
AAWTL
AAXQO
AAYOK
AAYXX
ABBUW
ABDIG
ABJNI
ABOCM
ABPMR
ABPXF
ABQRW
ABXVJ
ABZAD
ACCJW
ACDDN
ACDOF
ACEWG
ACGFO
ACGFS
ACILI
ACOAL
ACRKK
ACWDW
ACWRI
ACXNZ
ACZKN
ADBBV
ADCYY
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFCHL
AFDTB
AFEXH
AFFNX
AFNMH
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJJEV
AJNWD
AJNYG
AJZMW
ALKUP
ALMA_UNASSIGNED_HOLDINGS
AMJPA
AMNEI
ASPBG
AVWKF
AYCSE
AZFZN
BAWUL
BOYCO
BQLVK
BYPQX
C1A
C45
CITATION
CS3
DIK
DIWNM
DU5
DUNZO
E.X
E3Z
EBS
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FW0
GX1
H0~
H13
HZ~
H~9
IKREB
IKYAY
IN~
J5H
JF9
JG8
JK3
JK8
K-A
K-F
K8S
KD2
KMI
KQ8
L-C
L7B
M18
N4W
N9A
NEJ
N~7
N~B
O9-
OAG
OAH
OBH
OCB
OCUKA
ODMTH
OGEVE
OHH
OHT
OHYEH
OK1
OL1
OLB
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P2P
PQQKQ
RAH
RLZ
S4R
S4S
T8P
TEORI
TR2
UPT
V2I
VVN
W2D
W3M
W8F
WH7
WHG
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YOC
YSK
YYM
YYP
YZZ
ZFV
ZY1
ZZMQN
~H1
1CY
41~
AAQKA
AASCR
AASXQ
ABASU
ABVCZ
ABXYN
ABZZY
ACLDA
ACXJB
ADFPA
AEBDS
AFBFQ
AFMBP
AFSOK
AHQVU
AKCTQ
AKULP
ALMTX
AMKUR
AOHHW
AOQMC
BS7
EEVPB
EJD
ERAAH
FEDTE
GNXGY
GQDEL
HLJTE
HVGLF
IPNFZ
IQODW
MVM
N~M
ODA
P-K
R58
RIG
TSPGW
YQJ
YXB
ZGI
ZXP
ACIJW
ACRZS
AWKKM
CGR
CUY
CVF
ECM
EIF
NPM
OJAPA
OLW
PKN
RHF
7X8
ID FETCH-LOGICAL-c505t-a18c539fcfe7299e40e9166a9a3f2b9555a0f69a318287a4e79ae6494eced6493
ISSN 0009-7322
1524-4539
IngestDate Fri Jul 11 09:24:33 EDT 2025
Wed Feb 19 01:43:20 EST 2025
Mon Jul 21 09:11:54 EDT 2025
Tue Jul 01 02:05:08 EDT 2025
Thu Apr 24 23:08:51 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 20
Keywords Myocardial infarction
remodeling
Preservation
Stem cell
Cardiovascular disease
Instrumental dilatation
Glucose
Myocardial disease
Left ventricle
Granulocyte colony stimulating factor
cells
Heart disease
Revascularization
angioplasty
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c505t-a18c539fcfe7299e40e9166a9a3f2b9555a0f69a318287a4e79ae6494eced6493
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.105.541433
PMID 16275869
PQID 68802022
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_68802022
pubmed_primary_16275869
pascalfrancis_primary_17283722
crossref_primary_10_1161_CIRCULATIONAHA_105_541433
crossref_citationtrail_10_1161_CIRCULATIONAHA_105_541433
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2005-11-15
PublicationDateYYYYMMDD 2005-11-15
PublicationDate_xml – month: 11
  year: 2005
  text: 2005-11-15
  day: 15
PublicationDecade 2000
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
– name: United States
PublicationTitle Circulation (New York, N.Y.)
PublicationTitleAlternate Circulation
PublicationYear 2005
Publisher Lippincott Williams & Wilkins
Publisher_xml – name: Lippincott Williams & Wilkins
References e_1_3_2_26_2
e_1_3_2_49_2
e_1_3_2_28_2
(e_1_3_2_54_2) 2002; 425
e_1_3_2_41_2
e_1_3_2_43_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_9_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_1_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_58_2
e_1_3_2_3_2
e_1_3_2_14_2
e_1_3_2_35_2
e_1_3_2_56_2
e_1_3_2_50_2
e_1_3_2_27_2
e_1_3_2_48_2
e_1_3_2_29_2
e_1_3_2_40_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_25_2
e_1_3_2_46_2
(e_1_3_2_4_2) 1996; 94
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
(e_1_3_2_20_2) 1996; 23
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_32_2
(e_1_3_2_52_2) 2004; 110
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_57_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_55_2
e_1_3_2_2_2
(e_1_3_2_51_2) 2004; 110
16286600 - Circulation. 2005 Nov 15;112(20):3033-5
References_xml – volume: 94
  start-page: II-332
  year: 1996
  ident: e_1_3_2_4_2
  publication-title: Circulation
– ident: e_1_3_2_31_2
  doi: 10.1016/S0735-1097(98)00395-7
– ident: e_1_3_2_30_2
  doi: 10.1016/0735-1097(96)00152-0
– ident: e_1_3_2_39_2
  doi: 10.1038/nm1199
– ident: e_1_3_2_12_2
  doi: 10.1038/86498
– ident: e_1_3_2_25_2
  doi: 10.1016/0735-1097(94)90667-X
– ident: e_1_3_2_41_2
  doi: 10.1161/01.cir.0000147609.39780.02
– ident: e_1_3_2_28_2
  doi: 10.7326/0003-4819-134-8-200104170-00011
– ident: e_1_3_2_19_2
  doi: 10.1046/j.1365-2141.1997.8532481.x
– ident: e_1_3_2_57_2
  doi: 10.1096/fj.03-0637fje
– ident: e_1_3_2_14_2
  doi: 10.1161/01.cir.0000034046.87607.1c
– ident: e_1_3_2_38_2
  doi: 10.1161/01.cir.0000129770.93985.3e
– ident: e_1_3_2_7_2
  doi: 10.1161/circ.100.suppl_2.Ii-247
– ident: e_1_3_2_10_2
  doi: 10.1038/35070587
– volume: 23
  start-page: 1
  year: 1996
  ident: e_1_3_2_20_2
  publication-title: Transfus Med
– ident: e_1_3_2_35_2
  doi: 10.1161/01.res.0000151843.79801.60
– ident: e_1_3_2_40_2
  doi: 10.1161/circ.103.23.2776
– ident: e_1_3_2_3_2
  doi: 10.1056/NEJMoa012081
– ident: e_1_3_2_50_2
  doi: 10.1016/S0140-6736(04)15689-4
– ident: e_1_3_2_56_2
  doi: 10.1161/01.cir.0000027585.05868.67
– ident: e_1_3_2_44_2
  doi: 10.1161/circ.98.24.2695
– volume: 425
  start-page: 603
  year: 2002
  ident: e_1_3_2_54_2
  publication-title: Transfusion
– ident: e_1_3_2_24_2
  doi: 10.1161/circ.105.4.539
– ident: e_1_3_2_53_2
  doi: 10.1097/00062752-200105000-00005
– ident: e_1_3_2_18_2
  doi: 10.1016/S0195-668X(02)00618-8
– ident: e_1_3_2_8_2
  doi: 10.1016/S0092-8674(01)00409-3
– ident: e_1_3_2_48_2
  doi: 10.1161/01.cir.0000025609.13806.31
– ident: e_1_3_2_42_2
  doi: 10.1016/S0140-6736(03)14232-8
– ident: e_1_3_2_55_2
  doi: 10.1016/j.yjmcc.2004.03.005
– ident: e_1_3_2_37_2
  doi: 10.1038/nature02446
– ident: e_1_3_2_11_2
  doi: 10.1073/pnas.181177898
– ident: e_1_3_2_5_2
  doi: 10.1172/JCI119070
– ident: e_1_3_2_13_2
  doi: 10.1067/mtc.2002.120716
– ident: e_1_3_2_36_2
  doi: 10.1038/nature02460
– ident: e_1_3_2_17_2
  doi: 10.1002/stem.140090
– volume: 110
  start-page: 17-III-238.
  year: 2004
  ident: e_1_3_2_51_2
  publication-title: Circulation
– ident: e_1_3_2_23_2
  doi: 10.1016/S0894-7317(89)80014-8
– ident: e_1_3_2_27_2
  doi: 10.1097/00003072-199601000-00005
– ident: e_1_3_2_22_2
  doi: 10.1023/A:1005768523234
– ident: e_1_3_2_6_2
  doi: 10.1038/nm0898-929
– ident: e_1_3_2_9_2
  doi: 10.1016/S0092-8674(01)00328-2
– ident: e_1_3_2_49_2
  doi: 10.1161/circ.102.19.2329
– ident: e_1_3_2_47_2
  doi: 10.1056/NEJM200009283431303
– ident: e_1_3_2_29_2
  doi: 10.7326/0003-4819-134-8-200104170-00012
– ident: e_1_3_2_46_2
  doi: 10.1161/01.cir.0000062649.63838.c9
– ident: e_1_3_2_58_2
  doi: 10.1038/nm912
– ident: e_1_3_2_33_2
  doi: 10.1161/01.cir.0000051460.85800.bb
– ident: e_1_3_2_2_2
  doi: 10.1111/j.1749-6632.2001.tb03591.x
– ident: e_1_3_2_16_2
  doi: 10.1016/S0140-6736(03)12110-1
– ident: e_1_3_2_34_2
  doi: 10.1161/01.cir.0000099501.52718.70
– ident: e_1_3_2_32_2
  doi: 10.1056/NEJM200106213442503
– ident: e_1_3_2_43_2
  doi: 10.1016/S0140-6736(04)15695-X
– ident: e_1_3_2_26_2
  doi: 10.1007/BF01728306
– ident: e_1_3_2_45_2
  doi: 10.1161/01.cir.0000084828.50310.6a
– ident: e_1_3_2_1_2
  doi: 10.1161/circ.81.4.2138525
– ident: e_1_3_2_21_2
  doi: 10.1016/0002-9149(66)90191-3
– ident: e_1_3_2_15_2
  doi: 10.1016/j.jacc.2004.08.014
– volume: 110
  start-page: 17-III
  year: 2004
  ident: e_1_3_2_52_2
  publication-title: Circulation
– reference: 16286600 - Circulation. 2005 Nov 15;112(20):3033-5
SSID ssj0006375
Score 2.31652
Snippet Background— Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony–stimulating factor (G-CSF) mediates...
Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony-stimulating factor (G-CSF) mediates mobilization of...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 3097
SubjectTerms Adult
Biological and medical sciences
Blood and lymphatic vessels
Blood vessels and receptors
Cardiology. Vascular system
Coronary Angiography
Coronary heart disease
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Female
Fluorodeoxyglucose F18
Fundamental and applied biological sciences. Psychology
Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use
Heart
Hematopoietic Stem Cell Mobilization
Humans
Male
Medical sciences
Middle Aged
Myocardial Infarction - diagnostic imaging
Myocardial Infarction - physiopathology
Myocardial Infarction - prevention & control
Myocardial Infarction - therapy
Patient Selection
Positron-Emission Tomography
Radiopharmaceuticals
Recurrence
Stem Cell Transplantation
Ventricular Remodeling - physiology
Vertebrates: cardiovascular system
Title Preservation From Left Ventricular Remodeling by Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Use of Granulocyte-Colony–Stimulating Factor (FIRSTLINE-AMI)
URI https://www.ncbi.nlm.nih.gov/pubmed/16275869
https://www.proquest.com/docview/68802022
Volume 112
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9NAEIBXbZEqJISghRIeZZEQAkUOfj-OIWpJUNNDm0i5RWt7LCwSJ0qcQ_o7-UHM7Nqx0zaocHES2-tVtJ93dmbnwdjHWLcBwHc1I7Z0zfZ0TxO-B5oRhpBEPtVcJUWxf-l2h_aPkTPa22c1r6VVHraim3vjSv5nVPEcjitFyf7DyG4eiifwO44vHnGE8figMSb_idKoqgJFJpDkTXJhlHY9sWguQNa6IYMALjQTSlegbVJEyMiVwhW1iMeUmwmU3LlJJv2m9D4RpUMk4FwmDRAiIveC6RoF4UJGnuC_wTdG3ofdrNQGAfaRrVBYrnPQKDl2ttZwQpnKgmHkvylL_dAS97x3dT246F2eae1-r7RNlOkT0kVUlBi7r3JQzZKBU520znZp8_9bZwnrNKtm_vxmqape1QMFSNJMIFVW3S5KbRQBdYfl6-jnNI1zJZ_TX7BlI3EoWFBFibagmNdNW7MdlTdpM_EbZo1wU6_N45auvIbvChiXBEynd9UZXqh0xd021UpuUTl1ldKjBt58KskzKBW0r0rS3MruXV7aZ49MVHSoBsf3UeWk5Fqec8g-FD1_3dkv5b4tnrS1wHoyR4jEJFFFWnZrUXI1NXjGnhZqEG8rpp-zPciO2HE7E_lsuuafuHRMljs-R-ywX_h_HLPfdeI5Ec-JeF4jnlfE83DNbxPP7xDPkXhOxHMinlfE8zTjJfFcEs8r4nlFPHWDxPNZwv9OPFfE889bvH95wYbnZ4NOVyvqkmgR6gu5Jgw_QpSSKAFUTQOwdUAlyxWBsBIzDBzHEXri4i-DqkkIG7xAgGsHNkQQ46f1kh1kswxeMQ6JDq4FTuxath36jvBdMHC5GPpxYGHbBvPLwRxHRdJ-qh0zGUvl3TXG20jgaWeskGgwc9N0rjLXPKTR6RYxVUuP0mSZZoO9LxEaoyCigREZzFbLsYsrAVOnO04UWVXbgszXO6-8YY-r1_YtO8gXK3iHi_08PJXvwx8mEQRd
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preservation+from+left+ventricular+remodeling+by+front-integrated+revascularization+and+stem+cell+liberation+in+evolving+acute+myocardial+infarction+by+use+of+granulocyte-colony-stimulating+factor+%28FIRSTLINE-AMI%29&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Ince%2C+H%C3%BCseyin&rft.au=Petzsch%2C+Michael&rft.au=Kleine%2C+Hans+Dieter&rft.au=Schmidt%2C+Heike&rft.date=2005-11-15&rft.eissn=1524-4539&rft.volume=112&rft.issue=20&rft.spage=3097&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.105.541433&rft_id=info%3Apmid%2F16275869&rft.externalDocID=16275869
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon